These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 27223863

  • 1. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D, Mahler DA, Hanania NA.
    Expert Rev Respir Med; 2016 Jul; 10(7):767-80. PubMed ID: 27223863
    [Abstract] [Full Text] [Related]

  • 2. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 3. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

  • 4. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD.
    Weng CF, Wu CC, Wu MH, Lin FJ.
    Chest; 2023 Apr 06; 163(4):799-814. PubMed ID: 36442662
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M, Kunita Y, Shirahase K, Yamazaki R, Hanada S, Sawaguchi H, Tohda Y.
    BMC Pulm Med; 2021 Jan 13; 21(1):26. PubMed ID: 33441146
    [Abstract] [Full Text] [Related]

  • 7. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK, Yoshisue H, Lad R.
    Adv Ther; 2019 Mar 13; 36(3):495-519. PubMed ID: 30742242
    [Abstract] [Full Text] [Related]

  • 8. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul 13; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 9. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 13; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

  • 10. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul 13; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 11. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.
    Pulm Pharmacol Ther; 2019 Dec 13; 59():101855. PubMed ID: 31639476
    [Abstract] [Full Text] [Related]

  • 12. Dual bronchodilation for the treatment of COPD: From bench to bedside.
    Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG.
    Br J Clin Pharmacol; 2022 Aug 13; 88(8):3657-3673. PubMed ID: 35514240
    [Abstract] [Full Text] [Related]

  • 13. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.
    Price D, Østrem A, Thomas M, Welte T.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 13; 12():141-168. PubMed ID: 28115839
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
    Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.
    Pulm Pharmacol Ther; 2019 Dec 13; 59():101841. PubMed ID: 31520718
    [Abstract] [Full Text] [Related]

  • 15. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan 13; 55(1):2-5. PubMed ID: 28057707
    [Abstract] [Full Text] [Related]

  • 16. Which LABA/LAMA should be chosen in COPD patients in real life?
    Sposato B, Petrucci E, Serafini A, Lena F, Lacerenza LG, Montagnani A, Alessandri M, Cresti A, Scala R, Rogliani P, Ricci A, Perrella A, Scalese M.
    Pulm Pharmacol Ther; 2021 Dec 13; 71():102076. PubMed ID: 34530132
    [Abstract] [Full Text] [Related]

  • 17. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
    Gong Y, Lv Y, Liu H, Zheng Q, Li L.
    Ther Adv Respir Dis; 2022 Dec 13; 16():17534666211066068. PubMed ID: 35001708
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.
    Aziz MIA, Tan LE, Wu DB, Pearce F, Chua GSW, Lin L, Tan PT, Ng K.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 13; 13():3203-3231. PubMed ID: 30349228
    [Abstract] [Full Text] [Related]

  • 19. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
    Gong Y, Sui Z, Lv Y, Zheng Q, Li L.
    Eur J Clin Pharmacol; 2023 Oct 13; 79(10):1321-1332. PubMed ID: 37507595
    [Abstract] [Full Text] [Related]

  • 20. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.
    Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 13; 13():3115-3130. PubMed ID: 30323582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.